No, since Meloxicam is not an approved drug in the USA, there is no official withdrawal time for this compound. Similarly, this NSAID should not be used in racing since there are no guidelines available.
Frequently Asked Questions
Preliminary pharmodynamic data generated by NC State University and lameness score data as experienced by field practitioners, indicate a 3 to 4 day window of release and efficacy of this primarily Cox-2 inhibitor.
Meloxicam appears to be useful in most musculoskeletal lamenesses including suspensory and articular problems. The vehicle in which Meloxicam is formulated releases the active over a 3+ day period (data from North Carolina University). Field veterinarians report efficacy in improving lameness scores for 3 to 5 days, depending on severity, following a single IM injection.
The dose used also depends on the severity of the case and body weight of the patient. Doses used clinically in the field range from 750 to 1500 mg per 450 kg horse. Since Meloxicam is predominantly a selective Cox-2 inhibitor it may be safer than other Cox-1 + Cox-2 inhibitors such as Flunixin Meglumine and Phenylbutazone.
Yes, both the BioRelease Altrenogest LA (suppresses estrus for 12 days on average), and the BioRelease Altrenogest Microparticles LA (suppresses estrus for 30 days on average) can be used in FEI horses (MARES ONLY, cannot be used in geldings). Veterinarians prefer these two compounds because they can be administered before arriving at the show grounds and will be effective during the event.
Many veterinarians continue to use P+ (Progesterone + Estradiol in Oil) for a ten day treatment with prostaglandin F2 on the tenth day. Historically, this has required daily injections.
More recently, veterinarians have been using one 10 mL injection of P+ LA with a PGF2 injection 10 days later. Results have been reported as similar to the daily protocol.
Another newer protocol has utilized a single injection IM of BioRelease Altrenogest LA 225mg dose concomitant with PGF2 given on the same day. Practitioners report that mares are typically in estrus on day 13 after the injection and the grouping of ovulations is as good or better than that obtained with P+.
Technique of injection may be the most important component in experiencing or preventing a reaction. Many experienced veterinarians use one needle to draw up the solution and then switch to a clean needle with no drug on the outside to deliver the compound IM in sensitive horses. If injecting 5 mL, for example, inject into at least two different sites, using a total of 3 needles (1 to draw up the solution and second for the first injection and a third for the final injection of the compound). Remember there is no substitute for proper technique.
Information on IM injection technique is available on the web. We recommend http://www.aces.edu/pubs/docs/A/ANR-1018/ for a good review of proper injection technique.
Occasionally liquid formulations of both Altrenogest and native Progesterone have been reported, by practitioners, to cause some reaction at the injection site that seems to be similar to hives, suggesting an immune reaction. The reported incidence appears to be at a rate of about 7%. Microparticles use lactide-glycodide polymers that are extremely biocompatible and widely used in human products. These formulations are rarely associated with injection site reactions.
No, Compounding pharmacies are prohibited from copying approved formulations. Pharmacy reproduction of any FDA approved drug is prohibited by law. However, we do have two formulations that contain the same active ingredient: Altrenogest.
Our Altrenogest 500 mg MicroParticle formulation is an intramuscular injection that is given once every 30 days and our Altrenogest 150 mg/mL compound is given once every 12 days.
Most veterinarians prefer to use either of the compounded Altrenogest formulations.
(BioRelease Altrenogest LA 150 mg/mL or BioRelease Altrenogest Microparticles LA 500 mg). Many veterinarians prescribe the microparticle formulation and report no reaction at the injection site. Recent published research (Burns, et al. 2009 a,b) and clinical reports from veterinary practitioners suggest that these progestin compounds will suppress estrus for an average of 10 or 30 days, respectively. The onset of action has also been reported to be from 6 to 24 hrs. Burns, et al. 2008 and McCue, et al. 2008 have reported that compounded medroxy progesterone acetate (DEPO) did not affect or block estrous behavior in mares.
Once their veterinarian has faxed in a completed Prescription Form with refills, owners can call in with their refill information (prescription #, located on Rx bottle) directly to the pharmacy at our toll free number.
BET PHARM specializes in equine reproductive formulations that use controlled release delivery. Our staff is unique in that it includes world renowned experts in equine reproduction and controlled release drug delivery with decades of expertise. We also collaborate with experts around the world to assure that our formulations perform at the highest level. These efforts include extensive research & development, in vivo and in vitro testing as well as clinical trials including dozens of blinded controlled studies.